PMID- 30398028
OWN - NLM
STAT- MEDLINE
DCOM- 20190409
LR  - 20190409
IS  - 1756-185X (Electronic)
IS  - 1756-1841 (Linking)
VI  - 21
IP  - 10
DP  - 2018 Oct
TI  - Association study between killer immunoglobulin-like receptor polymorphisms and 
      ankylosing spondylitis disease: An updated meta-analysis.
PG  - 1746-1755
LID - 10.1111/1756-185X.13408 [doi]
AB  - BACKGROUND: Several genetic studies have assessed the association between 
      polymorphisms in killer immunoglobulin-like receptors (KIR) genes and 
      susceptibility of individuals to ankylosing spondylitis (AS), but the findings 
      have been inconclusive and incongruous. Therefore, we conducted this 
      meta-analysis of all case-control studies meeting the inclusion criteria for 
      obtaining an exact conclusion of the effect of KIR polymorphisms on the risk of 
      AS. METHODS: A systematic literature search was conducted in electronic 
      databases, including Scopus web of science, ScienceDirect, and PubMed to find all 
      eligible studies exploring the association between KIR polymorphisms and the risk 
      of AS, prior to June 2017. Pooled odds ratios (OR) and their corresponding 95% 
      CIs were used to evaluate the strength of the association between KIR 
      polymorphisms and the risk of AS. RESULTS: A total of 16 case-control studies, 
      encompassed in 12 papers, with 1770 cases and 2907 healthy subjects were included 
      in the meta-analysis. This meta-analysis revealed three significant positive 
      associations of 2DS1, 2DS5, and 3DS1 with susceptibility to AS, while two 
      significant negative associations of 2DL2 and 2DS2 with susceptibility to AS were 
      identified. In the subgroup analysis based on human leukocyte antigen (HLA)-B*27 
      positive patients and healthy subjects, results indicated that there were four 
      significant positive associations between 2DL5, 2DS4, 2DS5, 3DS1 polymorphisms 
      and susceptibility to AS in HLA-B*27-positive patients; a significant negative 
      association of 3DL1 in HLA-B*27-positive patients was found. CONCLUSIONS: While 
      2DS1, 2DS5, and 3DS1 polymorphisms increased AS risk, 2DL2 and 2DS2 polymorphisms 
      were associated with reduced AS susceptibility.
CI  - (c) 2018 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons 
      Australia, Ltd.
FAU - Rezaei, Ramazan
AU  - Rezaei R
AD  - Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, 
      Iran.
AD  - Department of Immunology, School of Medicine, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Mostafaei, Shayan
AU  - Mostafaei S
AD  - Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, 
      Iran.
AD  - Department of Community Medicine, Faculty of Medicine, Kermanshah University of 
      Medical Sciences, Kermanshah, Iran.
FAU - Aslani, Saeed
AU  - Aslani S
AD  - Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, 
      Iran.
FAU - Jamshidi, Ahmadreza
AU  - Jamshidi A
AD  - Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, 
      Iran.
FAU - Mahmoudi, Mahdi
AU  - Mahmoudi M
AUID- ORCID: 0000-0002-8164-8831
AD  - Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, 
      Iran.
LA  - eng
GR  - 96-02-41-35699/Tehran University of Medical Sciences/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20181105
PL  - England
TA  - Int J Rheum Dis
JT  - International journal of rheumatic diseases
JID - 101474930
RN  - 0 (Receptors, KIR)
SB  - IM
MH  - Case-Control Studies
MH  - Genetic Association Studies
MH  - Genetic Predisposition to Disease
MH  - Humans
MH  - Phenotype
MH  - *Polymorphism, Genetic
MH  - Prognosis
MH  - Protective Factors
MH  - Receptors, KIR/*genetics/immunology
MH  - Risk Assessment
MH  - Risk Factors
MH  - Spondylitis, Ankylosing/epidemiology/*genetics/immunology/prevention & control
OTO - NOTNLM
OT  - ankylosing spondylitis
OT  - killer immunoglobulin-like receptors
OT  - meta-analysis
OT  - polymorphism
EDAT- 2018/11/07 06:00
MHDA- 2019/04/10 06:00
CRDT- 2018/11/07 06:00
PHST- 2017/09/14 00:00 [received]
PHST- 2018/08/03 00:00 [revised]
PHST- 2018/09/14 00:00 [accepted]
PHST- 2018/11/07 06:00 [pubmed]
PHST- 2019/04/10 06:00 [medline]
PHST- 2018/11/07 06:00 [entrez]
AID - 10.1111/1756-185X.13408 [doi]
PST - ppublish
SO  - Int J Rheum Dis. 2018 Oct;21(10):1746-1755. doi: 10.1111/1756-185X.13408. Epub 
      2018 Nov 5.